Is this you? Create Your Porfile

Luis Barrera

Hospital Italiano de Buenos Aires

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Luis Barrera is active.

Explore More

Publication

Featured researches published by Luis Barrera.

International Journal of Laboratory Hematology | 2014

Frequent False‐positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin

Marta Martinuzzo; Luis Barrera; María Angélica D’Adamo; Juan Carlos Otaso; María Isabel Giménez; José Oyhamburu

Oral direct thrombin and Xa inhibitors are worldwide distributed for prevention and treatment of thrombosis. It is important to recognize their effects on lupus anticoagulant (LA) testing. The aim of the study is to describe the rate of false‐positive results of LA tests on plasmas of patients with previous negative LA tests results that receive dabigatran etexilate (DAB) 110 mg/twice a day, rivaroxaban (RIV) 10 mg/day or 15 mg/twice a day, or enoxaparin 40 mg/day.

Journal of Thrombosis and Haemostasis | 2018

The fibrinogen prothrombin time-derived method is not useful in patients anticoagulated with low molecular weight heparins or rivaroxaban

C. Duboscq; Marta Martinuzzo; J. Ceresetto; Marina Sol López; Luis Barrera; José Oyhamburu; G. Stemmelin

Essentials Fibrinogen prothrombin time‐derived (FIBPT‐d) behavior in anticoagulated patients is under studied. FIBPT‐d method overestimates fibrinogen in rivaroxaban and low molecular weight heparin samples. Unfractionated heparin and dabigatran samples showed similar bias to the control group. Rabbit brain and human recombinant thromboplastin behavior was different in rivaroxaban samples.

International Journal of Laboratory Hematology | 2015

Do PT and APTT sensitivities to factors' deficiencies calculated by the H47-A2 2008 CLSI guideline reflect the deficiencies found in plasmas from patients?

Marta Martinuzzo; Luis Barrera; M. Rodriguez; María Angélica D'Adamo; Marina Sol López; Juan Carlos Otaso

Clinical Laboratory | 2016

Validation of an Automated Immunoturbidimetric Assay for Fibrinogen/Fibrin Degradation Products Measurement and its Correlation to a Semi-Quantitative Latex Agglutination Test

Marta Martinuzzo; Cecilia Ujhelly; Luis Barrera; María Angélica D’Adamo; Marina Sol López; Juan Carlos Otaso; José Oyhamburu

Acta Bioquimica Clinica Latinoamericana | 2016

Inhibidores adquiridos de la coagulación: enfoque diagnóstico y casos especiales

Marina Sol López; Marta Martinuzzo; Agustina Fares Taie; Luis Barrera; María Angélica D’Adamo; Juan Carlos Otaso; José Oyhamburu

Hematología (B. Aires) | 2002

Coagulopatía grave por Lonomia

Paula Cárdenas; Jorge Arbelbide; Elsa Nucifora; Juan Carlos Otaso; Luis Barrera

International Journal of Laboratory Hematology | 2018

False-positive lupus anticoagulant results by DRVVT in the presence of rivaroxaban even at low plasma concentrations

Marta Martinuzzo; R. Forastiero; C. Duboscq; Luis Barrera; Marina Sol López; J. Ceresetto; Diana Penchasky; José Oyhamburu

Clinical Laboratory | 2018

Rivaroxaban Levels in Patients' Plasmas are Comparable by Using Two Different Anti Xa Assay/Coagulometer Systems Calibrated with Two Different Calibrators

Marta Martinuzzo; Cristina Duboscq; Marina Sol López; Luis Barrera; Estela Vinuales; José Ceresetto; Ricardo Forastiero; José Oyhamburu

Medicina-buenos Aires | 2017

Función renal y nivel plasmático de dabigatrán en el valle, medido por un ensayo de trombina diluida

Marta Martinuzzo; Cristina Duboscq; Estela Vinuales; Beatriz Girardi; Diana Penchasky; José Ceresetto; German Stemmelin; Victoria Otero; Luis Barrera; Marina Sol López; Juan Carlos Otaso; José Oyhamburu

Hematology & Transfusion International Journal | 2016